Last updated: February 16, 2026
What is NDC 49884-0270?
NDC 49884-0270 corresponds to Belantamab mafodotin-blmf (brand: Blenrep), a monoclonal antibody-drug conjugate approved by the U.S. Food and Drug Administration (FDA) on August 4, 2020. It is prescribed for relapsed or refractory multiple myeloma in patients who have received four prior therapies.
Market Overview
Indication and Usage:
Blenrep targets relapsed/refractory multiple myeloma, a disease with a niche but growing patient population. The drug's approval covers a specific segment: patients with four or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Patient Population Dynamics:
The U.S. multiple myeloma population exceeds 35,000 prevalent cases annually, with approximately 20-25% fitting the relapsed/refractory subset indicated for Blenrep. This segment is expected to grow at a compound annual growth rate (CAGR) of 3-4% driven by aging and increased detection.
Market Competition:
Blenrep faces competition from other therapies like CAR T-cell therapies (ide-cel, cilta-cel), bispecific antibodies, and immunomodulatory drugs. Market share distribution depends on efficacy, safety profiles, and approval timelines for new competitors.
Manufacturing and Supply:
As a biologic, Blenrep's production complexity influences market supply and pricing. Patent exclusivity extends until at least 2030, with potential for extension via method patents.
Market Size and Revenue Projections
| Year |
Estimated Patient Population |
Market Penetration |
Revenue Estimate (USD million) |
| 2023 |
~4,500 (initial) |
10% |
225 |
| 2024 |
4,635 |
15% |
339 |
| 2025 |
4,774 |
20% |
453 |
| 2026 |
4,917 |
25% |
583 |
| 2027 |
5,064 |
30% |
725 |
Assumptions:
- Steady annual patient population growth of 3%.
- Incremental increases in market penetration as awareness and prescribing patterns mature.
- Pricing based on current list price and negotiated discounts.
Current Pricing Landscape
List Price:
The wholesale acquisition cost (WAC) for Blenrep is approximately $14,100 per vial. Due to the dosing regimen, the average treatment course involves about 6 to 8 administrations, each requiring multiple vials, translating into:
- Per-Treatment Cost: ~$85,000 to $112,800
- Average treatment duration: 3-6 months, dependent on patient response
Net Price Considerations:
Reimbursement negotiations, rebates, and discounts reduce the net price to providers and payers. Estimated net prices range from $10,500 to $13,300 per vial, considering these factors.
Pricing Trends:
While list prices are stable, payer negotiations have limited wholesale price increases. Historically, biologic drugs of this complexity see annual list price increases capped at 3-5%.
Pricing Evolution and Market Drivers
Factors Impacting Price:
- Introduction of biosimilars has not yet been realized for Blenrep; patent protections prevent immediate biosimilar entry.
- Growing competition from CAR T-cell therapies and bispecific antibodies could pressure prices.
- Adoption driven by perceived benefits over existing therapies, including efficacy and tolerability.
Potential Price Reductions:
As more competitors enter, Blenrep prices could decline by 10-20% over the next 3-5 years, especially if biosimilars or generic-like biologics are approved.
Regulatory and Policy Impacts
Pricing and PBMs:
Third-party payers and pharmacy benefit managers (PBMs) are increasingly negotiating for value-based contracts. These negotiations could influence actual realized prices via rebates and reimbursement rates.
Policy Trends:
Recent proposals favoring drug price transparency and inflation caps might impact biologics pricing strategies.
Future Market Developments
-
FDA Approvals of Competitors:
Advancements in CAR T and bispecific antibody therapies may expand indications, influencing Blenrep’s market share.
-
Label Expansion:
Potential additional indications in earlier lines of therapy could expand the patient base and revenue.
-
Pricing Strategies:
Manufacturers may employ risk-sharing agreements or value-based pricing to maintain competitiveness.
Key Takeaways
- Blenrep, with an initial estimated peak market size of approximately $450 million in the U.S., is positioned in a niche of relapsed or refractory multiple myeloma patients.
- The current list price is around $14,100 per vial, translating into $85,000-$112,800 per treatment course, with net prices possibly lower due to payer negotiations.
- Market growth depends on patient population dynamics, competitive landscape, and regulatory developments.
- Pricing pressures are anticipated from emerging therapies, particularly CAR T-cell approaches, which could lead to a 10-20% decline over the coming five years.
- The biologic's patent life and lack of immediate biosimilar competition provide pricing stability in the near term.
FAQs
1. How does Blenrep's pricing compare to other multiple myeloma therapies?
Blenrep's list price (~$14,100 per vial) is comparable to other biologics but is higher than small-molecule drugs due to manufacturing complexity and targeted delivery.
2. What factors affect the net price paid by payers?
Rebates, discounts, and negotiation strategies influence the net price, often reducing the list price by 20-30%.
3. How might biosimilars influence Blenrep's pricing?
Biosimilar competition could lead to significant price reductions, though none currently exist for this drug.
4. Will new indications expand Blenrep's market share?
Potential label expansions in earlier lines of therapy could increase its patient base, but competition and positioning will also impact market share.
5. What are the risks to revenue growth?
Key risks include stronger competing therapies, reimbursement pressures, and regulatory changes affecting pricing.
Citations
[1] FDA. (2020). FDA Approves Blenrep for Multiple Myeloma.
[2] IQVIA. (2022). US Oncology Market Data.
[3] FDA. (2021). Patent and exclusivity data for biologics.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement and pricing reports.
[5] EvaluatePharma. (2022). Biologics pricing and market share analysis.
